Hazards of the LA wildfires necessitate awareness that first responders and those central to the fires may be at risk for ...

For patients with relapsed BRCA-mutated ovarian carcinoma, rucaparib produced a median OS of 19.4 months vs 25.4 months with chemotherapy in new findings.

Oncology nurses are familiar with the concept of financial toxicity, which refers to the significant financial burden cancer ...

AUTX-703, a novel, oral KAT2A/B degrader, has received fast track designation for use in relapsed/refractory AML.

Experts discuss the role of supportive therapies, such as antiemetics, nutritional support, and physical activity, in improving outcomes and patient comfort during treatment.

Key opinion leaders explore strategies for managing neurotoxicity in patients on ALK inhibitors, emphasizing monitoring practices and balancing symptom management with treatment efficacy.

What has been your experience managing weight gain with lorlatinib? How do you address the impact of weight gain on quality of life compared to treatment benefits?

Panelists discuss how emerging treatments, digital health tools, and enhanced care coordination could streamline disease ...

Panelists discuss how their lived experiences and insights as patients should inform research priorities, treatment development, and care delivery improvements while sharing hopes for a future cure ...